First-in-human study of palcitoclax (APG-1252), a novel dual Bcl-2/Bcl-xL inhibitor, demonstrated advantages in platelet safety while maintaining anticancer effect in U.S. patients with metastatic solid tumors.Nehal J. Lakhani, Yifan Zhai, Zhiyan Liang et al.|Journal of Clinical Oncology|2020Cited by 20
Decreased serum musclin concentration is independently associated with the high prevalence of sarcopenia in Chinese middle‐elderly patients with type 2 diabetes mellitusLei Fu, Xinhua Ye, Qing Zhang et al.|Journal of Diabetes Investigation|2023Cited by 5